Yahoo Finance3d
FDA Grants Fast Track Designation to Lipocine for LPCN 1148 as a Treatment for Sarcopenia in Patients with Decompensated Cirrhosis
LPCN 1148, an oral prodrug of bioidentical testosterone, was recently studied in a proof-of-concept (POC) Phase 2 study in patients with decompensated cirrhosis. Treatment with LPCN 1148 in the ...
Monthly Prescribing Reference2d
Novel Androgen Receptor Agonist Fast Tracked for Sarcopenia in Cirrhosis
LPCN 1148 is an oral prodrug of bioidentical testosterone containing testosterone dodecanoate, an androgen receptor agonist.
Nasdaq3d
Lipocine's LPCN 1148 Gets Fast Track Status To Treat Sarcopenia In Decompensated Cirrhosis Patients
According to National Institutes of Health, decompensated cirrhosis is an acute deterioration in liver function in a patient with cirrhosis. Fast Track Designation provides several benefits ...
Stockhouse4d
FDA Grants Fast Track Designation to Lipocine for LPCN 1148 as a Treatment for Sarcopenia in Patients with Decompensated Cirrhosis
LPCN 1148, an oral prodrug of bioidentical testosterone, was recently studied in a proof-of-concept (POC) Phase 2 study in patients with decompensated cirrhosis. Treatment with LPCN 1148 in the POC ...
Medscape2d
Management of Patients With Decompensated HBV Cirrhosis
In addition, the accuracy of MELD scores in predicting the natural history of patients with decompensated HBV cirrhosis has not been prospectively determined. Because the natural history of ...
Medscape5d
Management of Patients With Decompensated HBV Cirrhosis
These features make lamivudine a more appropriate treatment compared with IFN for patients with decompensated HBV cirrhosis. The recommended dose of lamivudine is 100 mg daily. Because lamivudine ...